01.05.2024 13:00:08 - dpa-AFX: GNW-Adhoc: ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA
(NYSE: ADCT) today announced that it will host a conference call and live
webcast on Monday, May 6, 2024 at 8:30 a.m. EDT to report financial results for
the first quarter 2024 and provide updates on recent progress against key
catalysts from the pipeline.
To access the conference call, please register here
(https://register.vevent.com/register/BI8ba16607b7aa4c7c9b4ac0ef61780bec).
Registrants will receive the dial-in number and unique PIN. It is recommended
that you join 10 minutes before the event, though you may pre-register at any
time. A live webcast of the call will be available under "Events and
Presentations" in the Investors section of the ADC Therapeutics website at
ir.adctherapeutics.com (https://ir.adctherapeutics.com/overview/default.aspx).
The archived webcast will be available for 30 days following the call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in
the field of antibody drug conjugates (ADCs). The Company is advancing its
proprietary ADC technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl)
received accelerated approval by the FDA and conditional approval from the
European Commission for the treatment of relapsed or refractory diffuse large B-
cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in
development in combination with other agents and in earlier lines of therapy. In
addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and
preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations
in London and New Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on LinkedIn
(https://www.linkedin.com/company/adc-therapeutics/).
ZYNLONTA(®) is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
In some cases you can identify forward-looking statements by terminology such as
"may", "will", "should", "would", "expect", "intend", "plan", "anticipate",
"believe", "estimate", "predict", "potential", "seem", "seek", "future",
"continue", or "appear" or the negative of these terms or similar expressions,
although not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to certain risks and uncertainties that
can cause actual results to differ materially from those described. Factors that
may cause such differences include, but are not limited to: the Company's
ability to achieve the decrease in total operating expenses for 2024 compared to
2022, the expected cash runway into 4Q 2025, the effectiveness of the new
commercial go-to-market strategy, competition from new technologies, and the
Company's ability to grow ZYNLONTA(®) revenue in the United States; Swedish
Orphan Biovitrum AB (Sobi(®)) ability to successfully commercialize ZYNLONTA(®)
in the European Economic Area and market acceptance, adequate reimbursement
coverage, and future revenue from the same; approval by the NMPA of the BLA for
ZYNLONTA(®) in China submitted by Overland ADCT BioPharma and future revenue
from the same, our strategic partners', including Mitsubishi Tanabe Pharma
Corporation, ability to obtain regulatory approval for ZYNLONTA(®) in foreign
jurisdictions, and the timing and amount of future revenue and payments to us
from such partnerships; the impact, if any, from data reported by the University
of Miami for their IIT in FL; the timing and results of the Company's or its
partners' clinical trials including LOTIS 5 and 7, ADCT 601 and 602 as well as
the Company's early-stage pipeline research projects, actions by the FDA or
foreign regulatory authorities with respect to the Company's products or product
candidates; projected revenue and expenses; the Company's indebtedness,
including Healthcare Royalty Management and Oaktree and Blue Owl facilities, and
the restrictions imposed on the Company's activities by such indebtedness, the
ability to repay such indebtedness and the significant cash required to service
such indebtedness; and the Company's ability to obtain financial and other
resources for its research, development, clinical, and commercial activities.
Additional information concerning these and other factors that may cause actual
results to differ materially from those anticipated in the forward-looking
statements is contained in the "Risk Factors" section of the Company's Annual
Report on Form 20-F and in the Company's other periodic reports and filings with
the Securities and Exchange Commission. These statements involve known and
unknown risks, uncertainties and other factors that may cause actual results,
performance, achievements or prospects to be materially different from any
future results, performance, achievements or prospects expressed in or implied
by such forward-looking statements. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this document. The
Company undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of this press
release, except as required by law.
CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com (mailto:Nicole.Riley@adctherapeutics.com)
+1 862-926-9040
Â